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ABSTRACT
Survival and changes in mean body mass of whole-body irradiated mice were determined to examine the
radioprotectant activity of 5-diethylsulfonamoylsalicylatocopper(II) [Cu(II) (5-DESS)]. One of four groups of 25
female C57BL/6 mice were treated subcutaneously (sc)with 0, 10, 20, 40, 60, 80, 100, or 120 gmol Cu(II)(5-
DESS)/kg of body mass 3 hours before exposure to 8.0 Gy, gamma irradiation. In this paradigm, doses of Cu(II)(5-
DESS) increased survival up to 92% above vehicle-treated control mice (P 0.008). Mean body mass
determinations revealed that mice treated with 80 to 120 gmol Cu(II)(5-DESS)/kg of body mass exhibited a smaller
decrease in body mass than other complex-treated groups. These results support the hypothesis that Cu(II)(5-DESS)
is an effective radioprotectant.
INTRODUCTION
Protecting tissues from harmful effects of ionizing radiation or facilitating recovery from radiation injury are
important in reducing injurious aspects of accidental, environmental, occupational, and therapeutic exposure to
radiation. Agents used for these purposes are of particular importance with regard to facilitating manned space travel
enabling prophylaxis or treatment of solar radiation injury, treatment of radiation injury due to exposure to
radioactive material from electric power generating facilities, as well as gamma-ray, x-ray, and ultraviolet
electromagnetic radiation generated by high voltage power distribution lines, radiotherapy of neoplastic tumors, and
electromagnetic radiation due to the transparency of the ozone layer [1]. Radioprotector and radiorecovery agents,
agents administered after radiation injury [2], are essential in planning the manned space program and decreasing the
adverse health effects of intended and accidental exposure to radiation.
In 1942, Dale observed that addition of colloidal sulfur and thiourea to an aqueous solution of
carboxypeptidase prior to x-irradiation protected the enzyme from inactivation [3]. Since this report, thousands of
compounds have been screened for use as radioprotectants [4,5]. The best known and most widely studied of these
compounds is S-2-(3-aminopropylamino)ethyl phosphorothiotic acid (WR-2721). However, WR-2721 is plagued
by two major problems, which are associated with all aminothiol-based compounds, high toxicity and an inability
to substantially increase survival when administered after irradiation [6].
The discovery that a cytostolic essential metalloelement-dependent enzyme, dicopper(II)dizinc(II)
Superoxide Dismutase (CuZnSOD), increased survival of lethally irradiated mice when administered both one hour
before and after irradiation [7], suggested a new approach to radiation protection. This new approach was consistent
with the recognition that radiation injury is increased in the presence of oxygen and the formation of superoxide
[8,9].
There is a rich history describing the occasional use of essential metalloelements, including Cu, as
radioprotective agents [5,10]. Most recently, the radioprotective effect of dicopper tetrakis-(3,5-diisopropylsalicylate),
[Cu(II)z(3,5-DIPS)4]. [Cu(II)z(3,5-DIPS)4] was examined based upon its SOD-mimetic activity [11]. It has
subsequently been shown that Cu(II)z(3,5-DIPS)4 is effective when given intraperitoneally, subcutaneously, or orally
at nontoxic doses either before or after irradiation [12-14]. Doses of Cu(II)z(3,5-DIPS)4 used in reported studies
range from one-fifth to one-hundredth of the acutely toxic dose for male or female mice respectively 12].
Steel et al. [14] found that 24 to 48 gmol Cu(II)z(3,5-DIPS)4/kg of body mass and 49 to 96 lamol
Cu(II)Cl,./kg of body mass given sc 24 hours prior to irradiation were radioprotective; while doses of 133 to 901
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lamol 3,5-diisopropylsalicylic acid/kg of body mass produced no radiation protection. It is most likely that copper
complexes formed in vivo following the administration of Cu(II)C12 ultimately account for its radioprotective effects
[2]. Use of complexes avoids irritation caused by injection of Cu(II)Clzor Cu(II)SO4 due to their strong Lewis
acidity and complexes are less acutely toxic than these inorganic forms of copper. Complexes also enable tissue
targeting with regard to propitious distribution of essential metalloelements.
Since Cu(II)z(3,5-DIPS)4 is a non-antigenic, SOD-mimetic complex [15] we addressed the question as to
whether or not other non-antigenic, SOD-mimetic copper complexes might also be effective radioprotectants.
Toward this end we studied the radioprotectant efficacy of another SOD-mimetic, copper(II) 5-
diethylsulfonamoylsalicylate [Cu(II)(5-DESS)]. Its ICs0 in the xanthine/xanthine oxidase-nitroblue tetrazolium
system was found to be 3.4 laM which is essentially the same as the ICs0of 1.5 laM found for Cu(II)z(3,5-DIPS)4.
To examine the radioprotectant activity of Cu(II)(5-DESS), female C57BL/6 mice were treated
subcutaneously (sc) with 0, 10, 20, 40, 60, 80, 100, or 120 lamol Cu(II)(5-DESS)/kg of body mass 3 hours before
being exposed to 8.0 Gy gamma irradiation. Body mass measurements were also recorded daily throughout the 30
day post-irradiation period to examine the effect of Cu(II)(5-DESS) on radiation-induced loss ofbody mass.
METHODS AND MATERIALS
5-Diethylsulfonamoylsalicylic acid (5-DESS) was synthesized as follows:
Five ml (0.048 moles) of diethylamine (Sigma) was placed in a 100 mL round bottom flask with a stirring bar and
warmed to 50C. 5-Chlorosulfonylsalicylic acid (2.47g, 0.01 mole) (Fischer Scientific) dissolved in 5 ml of
Tetrahydrofuran (Aldrich), was then slowly added to the round bottom flask with stirring. Five ml of 1N NaOH
(Mallinckrodt) was then added and the mixture heated at 50C for hr and then heated at 90C for one-half hour.
After cooling in an ice bath, concentrated HC1 was added dropwise with stirring until the pH reached 2.0. The
tetrahydrofuran was removed by flash evaporation and the filtered solid recrystallized from a 1:1 mixture of 95%
ethanol and deionized water. The off-white solid melted through the range of 135C to 136C. Elemental analysis
calculated for CIHNOS: C; 48.35, H; 5.49, N; 5.12, and S; 11.72%. Found: C; 48.17, H; 5.50, N; 4.93, and
S; 11.66%.
The copper complex of 5-DESS was synthesized by dissolving 0.2 g (0.73 mmol) of 5-DESS in 45 ml of
95% ethanol with 0.029 g (0.73 mmol) of aqueous NaOH in 15 ml of 95% ethanol. Cupric chloride dihydrate
(Mallinckrodt) (0.07g, 0.37 mmol), dissolved in 15 ml of 95% ethanol was added dropwise with vigorous stirring
After this solution was concentrated to two-thirds of the final volume and refrigerated for 3 days, a pale-blue
precipitate formed and was collected by filtration, washed with 95% ethanol, and dried at 40C ovemight. This
complex did not melt on heating but decomposed over the range of290C to 30 IC. Elemental analysis calculated
for CH3NOsSCu: C; 37.43, H; 4.30, N; 3.97, O; 27.22, S; 9.10, and Cu; 18.00%. Found: C; 37.58, H; 4.50,
N; 3.95, O; 27.09, S; 9.12, and Cu; 17.87%.
Propylene glycol (Sigma) was microbiologically sterilized by Millipore Filtration through a 0.2 laM filter.
One liter of a 1.4% mass/volume polyvinyl alcohol (Sigma) was prepared by dissolving 14 grams in 900 ml saline
at 90C with stirring, cooling to room temperature, and diluting to 1000 ml after removal of the stirring bar.
Solutions of Cu(II)(5-DESS) were prepared as follows. The complex (23 rag, 64 lamol) was first wetted
with 1.6 ml of propylene glycol in a glass Potter-Elvehjem homogenizer with a Teflon pestle. The resulting
emerald green solution was transferred to a graduated cylinder with 1.4% polyvinyl alcohol in saline, used to rinse
the homogenizer, to a total volume of 40 ml, and vortex stirred. This slow dilution produced a light-green colored
true solution. A volume of 0.5 ml of this solution contained 0.8 tmol of complex and provided the 40 tmol/kg of
body mass dose of Cu(II)(5-DESS). Ten or five ml of this solution was diluted with 10 or 15 ml of complete
vehicle (4% propylene glycol and 1.4% polyvinyl alcohol in saline), respectively and vortex stirred to obtain
solutions containing 20 or 10 lamol/kg of body mass dose per 0.5 ml of solution.
Solutions of 40, 60, or 80 lamol/kg of body mass were prepared by first wetting the complex (115 mg, 320
mol) with 4 ml of propylene glycol in a 10 ml beaker. This solution was stirred and transferred to a graduated
cylinder with 1.4% polyvinyl alcohol in saline to a total volume of 100 ml and vortex stirred. A volume of 0.5 m
contained 1.6 mol of complex and provided 80 lamol Cu(II)(5-DESS)/kg of body mass. Fifteen ml or 10 ml of the
3.2 lamol per ml solution was diluted with 5 ml or 10 ml of complete vehicle to obtain solutions containing 1.2
lamol or 0.8 mol per 0.5 ml of solution which provided 60 mol or 40 lamol Cu(II)(5-DESS)/kg of body mass
Solutions of 1.6, 2.0, 2.4 mol per 0.5 ml intended to administer 80, 100, 120 mol Cu(II)(5-DESS)/kg of body
mass were prepared by fh’st wetting the complex (69 mg, 196 lamol) with 1.6 ml of propylene glycol in a 10 ml
beaker and then the contents of the beaker transferred to a graduated cylinder and vortex stirred with enough 1.4%
polyvinyl alcohol to make 40 ml of a 2.40 mol per 0.5 ml of solution, providing 120 tmol Cu(II)(5-DESS)/kg of
body mass.
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Fifteen ml of this solution was then diluted with 3 ml of complete vehicle and vortex stirred to obtain 18
ml containing 2.0 tmol of Cu(II)(5-DESS) per 0.5 ml, providing a dose of 100 lamol/kg of body mass. Twelve ml
of the 2.4-lamol per 0.5 ml solution was then diluted with 6 ml of complete vehicle and vortex stirred to obtain 18
ml of a 1.6 mol per 0.5 ml of solution, providing a dose of 80 ktmol/kg of body mass.
Single dose samples (0.5 ml) were placed in metal-flee culture tubes prior to initiation of treatment and
following treatment of each group. These samples were analyzed for copper by atomic absorption spectrophotometry
using an IL model 155 spectrophotometer and established interference-flee methods to determine the actual treatment
dose. A diluted sample of Cation Cal, a synthetic plasma (American Hospital Supply)or a diluted solution of trace
metals (Environmental Resource Associates, Cat #500), served as external standards. Found values were within the
+5% range of the calculated value. This procedure is recommended to provide assurance that the actual dose given
is the intended dose. Mice were whole-body irradiated using a J.L. Sheperd and Associated 143-45 Cesium-137
irradiator with an existing dose-rate of 1.43, 1.35, or 1.30 Gy/min.
All animal experiments were approved by the Institution’s Animal Care and Use Committee which has an
Animal Welfare Assurance on file with the Office of Protection from Research Risks.
For each experiment, one hundred female C57BL/6 mice, purchased from the National Cancer Institute,
were randomly assigned to 20 Plexiglass cages and given food and water ad libitum. Four groups of 25 ten week
old (15 to 20 g) mice were treated sc at the nape of the neck 3 hours before an approximate LDs0/30 (8.0 Gy) dose of
gamma radiation. Survivor body mass was determined daily throughout the 30 day duration of each experiment.
Mice that have not died by day 30 following irradiation will experience long term survival in having overcome the
effects of irradiation Mean body masses for each treatment group were plotted without standard error bars for clarity.
The Fisher Exact Two-Tailed Test was used to statistically compare results obtained for vehicle-treated and
complex-treated groups. Percent change in survival due to treatment was calculated as follows: percent survival of
complex-treated group minus percent survival of the vehicle-treated group divided by the percent survival of the
vehicle-treated group multiplied by 100 equals percent change in survival.
RESULTS
As shown in Figure 1, treatment with 20 or 40 lamol Cu(II)(5-DESS)/kg of body mass caused a modest
increase in survival. These small and not statistically significant increases in survival were 15% or 30%,
respectively, greater than vehicle-treated mice. It is noteworthy that the duration of 100% survival following
irradiation increased with increasing dose of complex. Repeating this study using doses of 40, 60, or 80 ktmol/kg of
body mass caused greater increases in survival (Figure 2) to 66%, 66%, or 111% (P--0.01) respectively above
vehicle-treated mice. Treatment with doses of 80, 100, or 120 lamol Cu(II)(5-DESS)/kg of body mass increased
survival however only the 120 mol/kg dose produced a statistically significant (P=0.008) increase in survival
(Figure 3) and again it is clear that the duration of 100% survival following irradiation increased with increasing
dose of complex. These survival results are summarized in Table I.
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Figure 1. Survival of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 10 tmol (), 20 tmol (.), or
40 tmol (A) Cu(II)(5-DESS)/kg of body mass.
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Figure 2. Survival of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 40 tmol (), 60 lamol (), or
80 lamol (A) Cu(II)(5-DESS)/kg of body mass.
80 _-_-_-
70-
60-
50-
40-
30
5 10 15 20 25 30
TIME AFTER IRRADIATION(DAY)
Figure 3. Survival of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 80 tmol(), 100 mol (), or
120 lamol (A) Cu(II)(5-DESS)/kg of body mass.
Table 1. Radioprotectant Activities of Cu(ll) (5-DESS)
Doses of
Cu(ll) 5-DESS
(lamole/kg)
Percent Percent
Survival Increase P Value
0
10
20
40
0
40
60
80
0
80
100
120
52 0 P=I.0
60 15 P=0.78
68 30 P=0.39
36
60 66 P-0.16
60 66 P=0.16
76 111 P=0.019
48
68 42 P-0.17
68 42 P=0.17
92 92 P=0.0008
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As shown in Figure 4, 5, and 6, vehicle-treated and Cu(II)(5-DESS)-treated mice lost body mass after
irradiation. Surviving mice recovered body mass by day 20 to 25. Mice treated with larger doses of 100 or 120
gmol Cu(II)(5-DESS) kg of body mass (Figure 6) appear to have had smaller losses in body mass following
irradiation than any of the other treated mice. While there was very little difference in acute loss of body mass for
complex-treated mice, the 40 and 60 gmol Cu(II)(5-DESS)/kg treated mice appear to have lost slightly but not
sigmificantly more body mass than all other groups treated with Cu(II)(5-DESS).
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Figure 4. Mean body mass of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 10 gmol (), 20 gmol
(), or 40 lamol (A) Cu(II)(5-DESS)/kg of body mass. Standard error bars have been omitted for clarity.
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Figure 5. Mean body mass of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 40 lamol (), 60 lamol
(m), or 80 lamol (,i) Cu(II)(5-DESS)/kg of body mass. Standard error bars have been omitted for clarity.
DISCUSSION
Doses of Cu(II)(5-DESS) used in this study ranged from 10 to 120gmol/kg of body mass or 0.2 to 2.4
gmol/mouse. All of these doses were non-toxic as evidenced by the lack of acute toxicity associated death in
complex-treated groups prior to deaths occurring in vehicle-treated groups.
Since Cu(II)(5-DESS) increases survival when given prior to irradiation to facilitate physiological and
biochemical responses following radiation injury, it is termed a radioprotective agent [2]. It seems improbable that
radioprotectant activities of this complex are exclusively due to its superoxide dismutase-mimetic activity. Doses
used in treatment would appear to be insufficient to be propitiously distributed to all tissues of 15 to 20 gm mice
and enable increased survival. Distribution to key hematopoietic tissues may allow recovery of immune responses
via de novo synthesis of Cu-dependent enzymes 12], including Cu-dependent SOD, and survival.
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Figure 6. Mean body mass of 8.0 Gy whole-body irradiated mice treated with vehicle (O), 80 amol (), 100 tmol
(g), or 120 tmol (A) Cu(II)(5-DESS)/kg of body mass. Standard error bars have been omitted for clarity.
Studies by Soderburg et al. [15-17] have demonstrated that Cu(II)2(3,5-DIPS)4, which has both
radioprotectant and radiorecovery activity, causes a rapid increase in recovery of immunocompetency when given
either before or ater irradiation. This recovery of immunocompetency is suggested to be due to facilitation of
copper-dependent enzymes that have a role in maintaining immunocompetency. It is likely that radioprotectant
activities of Cu(II)(5-DESS) are due to the ability of the complex to facilitate de novo synthesis of copper-dependent
enzymes 12] required for rapid recovery of immunocompetency.
In recent years, there has been considerable interest in the role of copper in overcoming inflammatory
disease states and facilitating tissue repair. One of the earliest (1940) uses of a copper compound as an anti-
inflammatory drug was the use of allocupreide sodium as an anti-arthritic agent 18].
Subsequently, many copper complexes including salicylates have been found to have a variety of anti-
inflammatory activities including: anti-polyarthritic, anti-ulcer, anti-convulsant, anti-cancer, analgesic, anti-diabetic,
anti-carcinogenic, anti-mutagenic, anti-inflammatory bowel syndrome, prevention of ischemia-reperfusion injury,
radioprotectant, and radiorecovery activites [18-20]. Since whole-body radiation injury is a model of whole-body
inflammatory disease, the demonstration of radioprotectant activity for Cu(II)(5-DESS) is a demonstration of anti-
inflammatory activity for this complex. Cu(II)(5-DESS) may also have other anti-inflammatory activities as well.
Studies of biochemical systems that mechanistically account for these antiinflammatory activities have
revieled that copper complexes modulate: lysyl oxidases, eicosanoid syntheses and arachidonate metabolism,
CuzZn2 SODs and demonstrate SOD-mimetic activity, stabilization of synovial and polymorphonuclear leukocyte
lysosomal membranes, histaminic activity, lymphocyte mitogenic and chemotactic responses, stabilization of
gamma-gobulin, GSH status, GSH-S-transferase, preprothrombin carboxylase, cytochrome P-450 monooxygenases,
and/or NADPH-dependent P-450 reductases, 2-oxoglutarate-dependent hydroxylase, lipid peroxidation, angiogensis,
and luteinizing hormone-releasing hormone secretion [18 and citations therein] as well as down-regulate nitric oxide
synthase [21 ].
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